Autosomal Dominant Nonsyndromic Hearing Loss 24

Autosomal dominant nonsyndromic hearing loss 24—often shortened to DFNA24—is a rare, inherited type of hearing loss. “Autosomal dominant” means a person needs just one changed copy of the gene to have the condition, so an affected parent has a 50% chance of passing it to each child. “Nonsyndromic” means the hearing loss occurs by itself without other medical features such as vision, heart, or kidney problems. For DFNA24 specifically, researchers mapped the cause to a region near the end of chromosome 4 (4q35–qter) in a large Swiss-German family. The exact gene has not yet been identified, so DFNA24 is considered a locus (a mapped location) rather than a named gene disorder. In that family, the hearing loss was sensorineural, bilateral (both ears), began before speech develops (prelingual), and the audiogram showed a steeply down-sloping pattern (worse in high frequencies). Early work described it as non-progressive; later, a detailed follow-up in the same family showed slow, lifelong progression of the hearing thresholds. Karger Publishers+3PubMed+3PMC+3

---

Other names

• DFNA24

• Deafness, autosomal dominant 24

• Autosomal dominant nonsyndromic deafness 24

• Autosomal dominant nonsyndromic hearing loss 24
  (These all refer to the same locus on 4q35–qter.) Monarch Initiative+1

---

Types

Because the gene is still unknown, doctors “type” DFNA24 by clinical pattern:

1. By onset: usually prelingual (starts before language develops). PubMed

2. By laterality: bilateral (both ears). PMC

3. By kind of loss: sensorineural (inner-ear/nerve). PMC

4. By audiogram shape: steeply down-sloping, high frequencies worse than low. PMC

5. By course: likely slowly progressive across life (even if early papers suggested otherwise). Karger Publishers

6. By syndromic features: nonsyndromic (hearing only; no consistent extra-ear findings). PubMed

7. By inheritance: autosomal dominant (vertical transmission across generations). PMC

---

Causes

In DFNA24, the primary cause is a pathogenic change somewhere within the 4q35–qter region. Below are factors that either represent that cause or commonly modify/worsen the hearing over a lifetime. I’ll clearly mark the primary cause vs. modifiers.

Primary, disease-defining cause

1. A disease-causing DNA change within 4q35–qter (DFNA24 locus). This inherited change disrupts normal hearing biology in a dominant way. (Exact gene unknown; mapping is secure.) PubMed+1

Genetic context and inheritance factors (how/why it runs in families)

2. Autosomal dominant inheritance. One altered copy is enough to cause hearing loss; each child has a 50% chance to inherit it. PMC

3. De novo (new) variant at the DFNA24 locus (possible, though not specifically reported for DFNA24; recognized in dominant deafness). PMC

4. Variable expressivity. Same family, different degrees of hearing loss because of other genetic/environmental influences (common in DFNA conditions). MDPI

5. Modifier genes. Other genes can subtly worsen or improve thresholds over time (shown across DFNA conditions; DFNA24 likely similar). MDPI

Non-genetic modifiers (do not cause DFNA24, but can worsen the hearing once someone has it)

6. Age-related change (presbycusis) on top of DFNA24. Aging can add extra hearing loss beyond the DFNA baseline. PMC

7. Loud-sound exposure (noise). Past or ongoing noise accelerates later hearing decline. PMC+1

8. Aminoglycoside antibiotics (e.g., gentamicin) at high/risky exposure. PMC

9. Platinum chemotherapy (e.g., cisplatin). PMC

10. Loop diuretics (e.g., furosemide) at high/IV doses or with other risks. PMC

11. Salicylates at high doses (usually temporary but can worsen hearing while taken). Medscape

12. Head trauma (inner-ear concussion can aggravate thresholds) — general audiology principle in genetic HL. MDPI

13. Recurrent middle-ear infections (conductive components can mask/compound the sensorineural loss). MDPI

14. Viral illnesses affecting the inner ear (e.g., viral labyrinthitis). MDPI

15. Metabolic stressors (e.g., poorly controlled diabetes can worsen cochlear microvasculature—general modifier). MDPI

16. Smoking (vascular/cochlear oxidative stress; associated with worse thresholds) — general risk factor. MDPI

17. Occupational solvent exposure (e.g., toluene) — known ototoxic co-factors. MDPI

18. Recreational loud music via headphones/earbuds (unsafe listening). The Guardian

19. Cardiovascular risk factors (microvascular impact on the cochlea). MDPI

20. Combined risks (e.g., noise plus aging causes more synapse loss than either alone). Frontiers

---

Symptoms

1. Reduced hearing in both ears, often noticed early in life. PubMed+1

2. Trouble with high-pitched sounds (birds, beeps, children’s voices) because the loss is steeper in the high frequencies. PMC

3. Difficulty understanding speech in noise, such as restaurants or busy streets. (Typical for high-frequency sensorineural loss.) PMC

4. Mishearing consonants like “s,” “f,” “th,” which live in high frequencies. PMC

5. Needing higher TV or device volume compared with others. (Common functional complaint in sensorineural loss.) MDPI

6. Asking for repetition (“What?” “Pardon?”), especially in noisy places. MDPI

7. Teacher or caregiver noticing delayed responses or inconsistent attention to sound in childhood (because onset is prelingual). PubMed

8. Tinnitus (ringing or buzzing), which often accompanies sensorineural loss. MDPI

9. Listening fatigue—needing extra effort to follow conversations. MDPI

10. Slow worsening across years, subtle at first, more noticeable in teens/adulthood (progression can be slow). Karger Publishers

11. Better hearing in quiet, one-to-one settings than in groups. MDPI

12. Normal ear appearance on exam (ear canal and eardrum look healthy). (Nonsyndromic, sensorineural.) PMC

13. Family pattern of hearing loss across generations. PMC

14. No typical balance problems (vestibular symptoms are not a hallmark for DFNA24). PMC

15. No consistent extra-ear features (eyes, teeth, kidneys usually unaffected). (That’s what “nonsyndromic” means.) PubMed

---

Diagnostic tests

A) Physical examination

1. General ENT exam (head & neck). Checks overall health and any syndromic clues (usually absent in DFNA24). Confirms there’s no wax, infection, or outer-ear cause. PMC

2. Otoscopy. Looks at the ear canal and eardrum to rule out blockage or perforation; typically normal in DFNA24. PMC

3. Family pedigree assessment. Maps who in the family has hearing loss and at what ages to see a dominant pattern. PMC

4. Developmental and speech-language screen (children). Because onset is prelingual, early hearing loss can affect speech unless identified and supported early. PubMed

B) Manual bedside tests

5. Weber tuning-fork test. In sensorineural loss, sound localizes to the better ear (or midline if symmetric). Helpful quick screen. MDPI

6. Rinne tuning-fork test. Air conduction remains better than bone conduction (AC>BC) in sensorineural loss, supporting an inner-ear/nerve issue. MDPI

7. Functional listening tasks (quiet vs. noise). Simple, real-world checks that mirror the person’s complaints before formal audiology. MDPI

C) Lab and pathological / genetic tests

8. Targeted genetic testing (hereditary hearing-loss panel). Panels can confirm many DFNA genes; for DFNA24, the gene is unknown, so panels mainly exclude other DFNA causes and support linkage in research. Hereditary Hearing Loss

9. Exome or genome sequencing (research/advanced clinical). May detect rare variants and support mapping within 4q35–qter in families. Hereditary Hearing Loss

10. Copy-number analysis (e.g., CMA/MLPA) if a structural change in 4q is suspected. (General approach in genetic HL.) Hereditary Hearing Loss

11. Basic labs only when indicated (e.g., thyroid, glucose, autoimmune markers) to rule out syndromic or acquired causes if history suggests them. DFNA24 itself is nonsyndromic. MDPI

12. Pharmacogenetic/ototoxic risk review before giving drugs like aminoglycosides or cisplatin, to limit added damage. PMC

D) Electrodiagnostic and physiologic tests

13. Pure-tone audiometry. Gold standard to measure thresholds; DFNA24 typically shows bilateral, high-frequency, down-sloping sensorineural loss. PMC

14. Speech audiometry (SRT and word recognition). Quantifies how well speech is detected and understood; often reveals difficulty in noise. PMC

15. Tympanometry & acoustic reflexes. Middle ear usually normal; reflex patterns help confirm cochlear (not conductive) pathology. MDPI

16. Otoacoustic emissions (OAEs). Reduced/absent in affected high frequencies, supporting outer hair cell dysfunction typical of sensorineural loss. MDPI

17. Auditory brainstem response (ABR). Objective measure (useful in infants); thresholds track behavioral audiogram and can show cochlear rather than neural timing issues. MDPI

E) Imaging tests

18. High-resolution temporal-bone CT. Usually normal in nonsyndromic genetic loss; done to exclude structural anomalies if the story is atypical. MDPI

19. MRI of the internal auditory canals/brain. Rules out nerve malformations or retrocochlear pathology if needed (again, typically normal in DFNA24). MDPI

20. Cochlear implant work-up imaging (CT and/or MRI) if candidacy is considered in severe cases; ensures anatomy is suitable. MDPI

Non-pharmacological treatments (therapies & other options)

Note up front: these are the core, evidence-supported options used for DFNA24 and similar genetic sensorineural losses. I’m focusing on practical benefit, purpose, and mechanism in plain English.

1) Hearing aids (digital, frequency-shaped amplification).
Purpose: Make soft and speech sounds audible without making loud sounds uncomfortably loud.
Mechanism: Microphones capture sound, a digital chip selectively amplifies frequencies where hearing is reduced (often mid/high for DFNA24), and the receiver delivers tailored output to the ear canal. Good fitting plus real-ear verification improves clarity and comfort. nidcd.nih.gov

2) Cochlear implant (CI) evaluation and implantation (if indicated).
Purpose: Restore access to sound when hearing aids don’t give enough benefit.
Mechanism: A CI bypasses damaged inner-ear hair cells and directly stimulates the auditory nerve using an internal electrode array and external processor. FDA-approved systems list candidacy by age and aided speech understanding; children benefit from early implantation. U.S. Food and Drug Administration+1

3) Electro-acoustic stimulation (EAS/“hybrid” CI) for residual low-frequency hearing.
Purpose: Combine acoustic amplification of low tones with electrical stimulation of mid/high tones in the same ear.
Mechanism: Preserves and uses remaining inner-ear function while adding implant-based clarity for speech consonants; helpful in steeply sloping losses. (This is a clinical strategy referenced within CI practice and selection criteria.) NCBI

4) Bone-anchored hearing devices (in select cases).
Purpose: Support hearing when conventional earmolds aren’t tolerated or when anatomy/medical issues complicate ear-canal fittings.
Mechanism: Transmits sound through bone to the inner ear; used more often for conductive/mixed loss but can aid some special SNHL scenarios as part of individualized planning. nidcd.nih.gov

5) Remote microphone (FM/Roger) systems.
Purpose: Improve signal-to-noise ratio in classrooms, meetings, or noisy places.
Mechanism: A talker-worn or table microphone streams speech directly to hearing aids/implants, reducing the impact of distance and background noise. nidcd.nih.gov

6) Captioning and communication access technology.
Purpose: Ensure real-time access to spoken content in school, work, teleconferences, and media.
Mechanism: Live human captions or automatic speech recognition displays text; pairing with neckloops/streamers routes audio directly to hearing devices. nidcd.nih.gov

7) Auditory–verbal therapy & speech-language therapy.
Purpose: Build listening and spoken-language skills in children; optimize speech understanding strategies in all ages.
Mechanism: Structured listening practice, caregiver coaching, and language-rich routines help the brain make best use of amplified or electrically coded sound. (Recommended within habilitation frameworks.) NCBI

8) Tinnitus counseling and sound therapy (if tinnitus is present).
Purpose: Reduce distress and improve concentration and sleep.
Mechanism: Education plus low-level sound enrichment reduces the contrast between tinnitus and silence; hearing aids/CI often reduce tinnitus perception by restoring input. NCBI

9) Educational and workplace accommodations.
Purpose: Ensure equitable access and performance.
Mechanism: Preferential seating, captioned media, assistive listening systems, written supports, and quiet meeting spaces reduce listening effort and fatigue. nidcd.nih.gov

10) Noise exposure control & safe-listening habits.
Purpose: Protect remaining hearing and slow progression from preventable damage.
Mechanism: Use hearing protection, keep personal-device volumes moderate, and limit time in loud venues following WHO safe-listening guidance (e.g., ~80 dB for ≤40 h/week; ~90 dB for ≤4 h/week). World Health Organization+1

(Additional practical measures often included in care plans: family education, peer support, accessible alarms/telephones/doorbells, smartphone-based speech-to-text, and regular audiology follow-up.) nidcd.nih.gov

---

Drug treatments

There is currently no FDA-approved medicine that specifically treats or reverses genetic sensorineural hearing loss such as DFNA24. Care pathways rely on hearing technology and rehabilitation. Experimental work in otoprotective and inner-ear regenerative drugs is ongoing, but not yet approved for routine clinical use in hereditary nonsyndromic hearing loss. Frontiers+1

Because you asked for “20 drug treatments” from accessdata.fda.gov for this condition, it’s important to be transparent: Drugs@FDA has no approvals listing DFNA24 (or genetic nonsyndromic SNHL) as an indication. The FDA pages for hearing interventions focus on devices (e.g., cochlear implants), not disease-specific pharmacotherapy. Any list of “20 drugs for DFNA24” would be misleading or off-label and not evidence-based for this diagnosis. U.S. Food and Drug Administration+1

---

Dietary molecular supplements

No supplement cures DFNA24. A few nutrients are under study for general inner-ear health or specific scenarios, but evidence is mixed and often not disease-specific. If families choose supplements, they should do so in consultation with clinicians to avoid interactions and false expectations.

• Magnesium: RCTs and reviews suggest magnesium can reduce noise-induced hearing damage and may aid recovery in sudden SNHL when used adjunctively with steroids; this is not DFNA24-specific. Mechanism may include improved cochlear blood flow and anti-excitotoxic effects. Typical studied oral doses vary; high doses can cause diarrhea and interact with some medications. SAGE Journals+1

• Coenzyme Q10 (CoQ10): Small trials and disease-specific reports (e.g., mitochondrial CoQ10 deficiency) suggest potential benefit in some hearing contexts; evidence in hereditary nonsyndromic loss is limited. Mechanism relates to mitochondrial antioxidant support. Doses in studies vary; CoQ10 can interact with anticoagulants. PMC+1

• Omega-3 fatty acids (DHA/EPA): Observational data link higher omega-3 intake or blood levels with lower risk of age-related hearing loss; randomized trials for hereditary loss are lacking. Mechanisms may include anti-inflammation and better cochlear blood flow. Food sources are preferred over pills for safety. PMC+1

(Bottom line: supplements may have adjunctive roles for general ear health or other hearing conditions, but none has robust DFNA24-specific evidence.)

---

Immunity boosters, regenerative, and stem-cell drugs

There are no FDA-approved stem-cell or gene-therapy products for hearing loss at this time. FDA cautions consumers about unapproved stem-cell/exosome products marketed for many conditions, including hearing loss. While early clinical research in inner-ear gene therapy (e.g., OTOF-related deafness) is promising, it remains investigational and not a standard treatment for DFNA24. U.S. Food and Drug Administration+1

---

Surgeries

Cochlear implant surgery.
Procedure: An outpatient or short-stay operation places an internal receiver and an electrode array into the cochlea through a small mastoid and cochleostomy/round-window approach. Activation occurs a few weeks later, followed by regular programming (“mapping”).
Why it’s done: For severe-to-profound bilateral SNHL with poor aided speech understanding, to restore access to spoken sound and improve communication outcomes. U.S. Food and Drug Administration

Electro-acoustic (hybrid) CI surgery.
Procedure: Similar to CI but with surgical techniques and device designs aiming to preserve low-frequency hearing.
Why it’s done: For steeply sloping losses where preserving low-frequency acoustic hearing plus implant-provided high-frequency information yields the best speech clarity. NCBI

Bone-anchored hearing system implantation.
Procedure: A small titanium implant (or magnet) is anchored to skull bone; an external processor snaps on.
Why it’s done: Mainly for conductive/mixed losses or single-sided deafness; occasionally considered when ear-canal fittings are not feasible and a multidisciplinary team thinks it will help function. nidcd.nih.gov

Middle-ear implant (selected systems).
Procedure: An implant vibrates the ossicles or round window.
Why it’s done: For patients who cannot use conventional aids and are not CI candidates; candidacy is individualized and less common than hearing aids or CIs. nidcd.nih.gov

Assistive listening infrastructure (classroom/venue systems).
Procedure: Not a “surgery,” but often installed as part of a person’s care plan—loop systems or remote microphones integrated into schools and workplaces.
Why it’s done: To provide consistent, high-quality access to speech in real-world settings where background noise otherwise overwhelms amplified sound. nidcd.nih.gov

---

Prevention tips

1. Protect your ears from loud sound with earplugs/earmuffs in concerts, traffic, factories, and sports events. World Health Organization

2. Practice safe listening with headphones: keep volume moderate and limit time; follow WHO time-at-level guidance. World Health Organization

3. Avoid ototoxic medicines when safer alternatives exist; ask your clinician about aminoglycosides, cisplatin, loop diuretics, and high-dose salicylates. PMC

4. Consider MT-RNR1 testing before aminoglycosides in high-risk settings; certain variants greatly raise ototoxic risk. PMC+1

5. Vaccinate and treat ear infections promptly to reduce avoidable inner-ear stress. (General good practice within hearing-health programs.) NCBI

6. Use remote microphones/captioning in noisy environments to reduce listening fatigue. nidcd.nih.gov

7. Schedule routine audiology checkups and device reprogramming to keep amplification matched to your thresholds. NCBI

8. Prioritize cardio-metabolic health (exercise, sleep, nutrition), which correlates with healthier aging ears. (Emerging auditory-aging literature.) PMC

9. Family counseling and early intervention for children—early sound access supports language, school, and social development. NCBI

10. Use hearing protection rules at work; employers must run conservation programs at ≥85 dBA (8-h TWA). OSHA

---

When to see a doctor or audiologist (red flags)

See an audiologist and ENT/otologist if you notice new hearing difficulty, family history of early hearing loss, poor school performance linked to listening, asymmetric hearing (one ear much worse), sudden hearing drop, persistent tinnitus, or listening fatigue in noise. Sudden sensorineural loss is a medical urgency—seek care immediately. Genetic counseling is appropriate for families with autosomal-dominant patterns. NCBI

---

What to eat / what to avoid

What to eat: A balanced, Mediterranean-style pattern with fish (natural omega-3s), vegetables, fruits, legumes, whole grains, and nuts supports vascular and anti-inflammatory health that may help protect aging ears. Observational data link omega-3 intake with lower risk of age-related hearing loss. Hydration and general nutrition help energy and attention for listening. PMC+1

What to avoid/limit: Ultra-processed, high-salt, and high-sugar patterns that worsen cardio-metabolic health; self-prescribing high-dose supplements (e.g., fish-oil capsules) without clinician advice—benefit is unproven for DFNA24 and pills can carry risks. Keep alcohol and caffeine moderate if tinnitus is bothersome. Most importantly, avoid high-level noise and ototoxic drugs where alternatives exist. The Guardian+1

---

FAQs

1) Is DFNA24 the same as a gene name?
No. DFNA24 is a locus name (a mapped region on chromosome 4q35-qter). The exact gene remains unconfirmed. PubMed+1

2) Does DFNA24 cause other body problems?
No. By definition it is nonsyndromic (hearing issues only). NCBI

3) Is the hearing loss always the same in every family member?
No. Severity and progression may vary, even within the same family. NCBI

4) Do any medicines cure DFNA24?
No FDA-approved drug cures genetic sensorineural loss. Care uses hearing technology and therapy. Frontiers

5) Are cochlear implants safe and effective?
CIs are FDA-regulated devices with well-described benefits and risks; they help many people who get little benefit from hearing aids. U.S. Food and Drug Administration

6) Will a CI stop the hearing from getting worse?
A CI restores access to sound; it doesn’t change the underlying genetics. Programming and therapy maximize outcomes. NCBI

7) Can supplements fix DFNA24?
No. Some nutrients (magnesium, CoQ10, omega-3s) have limited evidence in other hearing contexts, not DFNA24 specifically. Food-first and clinician-guided use is safest. SAGE Journals+2PMC+2

8) Is gene therapy available now?
No approved gene therapy for hearing loss yet, though trials for some genes are underway. Children’s Hospital of Philadelphia

9) Could loud noise make DFNA24 worse?
Yes. Protect your ears—follow WHO safe-listening rules. World Health Organization

10) Should children be fitted early?
Yes. Early sound access (aids or CI) supports speech, language, and learning. NCBI

11) Are there tests for ototoxic risk?
Yes. MT-RNR1 testing identifies people at high risk for aminoglycoside-induced hearing loss so alternatives can be considered. PMC

12) How often should we repeat hearing tests?
At least yearly for stable loss; more often in growing children or if hearing seems to change. NCBI

13) Do captions and remote microphones really help?
Yes—both increase access to speech in noise or at a distance and reduce listening fatigue. nidcd.nih.gov

14) Are there risks with fish-oil pills?
Yes—supplements can have side effects and mixed cardiovascular data. Prefer food sources and ask your clinician before starting pills. The Guardian

15) What’s the single most important thing we can do today?
Ensure consistent access to sound (well-fitted hearing aids or CI evaluation), protect from loud noise, and set up ongoing audiology and speech-language support. nidcd.nih.gov+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 03, 2025.